Navigation Links
Fingerprinting prostate cancer

Two new genes which are active in prostate cancer have been identified by US researchers. At a molecular level, cancer tissue differs markedly from normal healthy tissue in its pattern of gene activity. Researchers have now developed the tools that can visualise analyse these 'molecular fingerprints' that characterise the cancerous cell. Using microarray technology, it's now possible to analyse thousands of genes in one experiments.//

Doctors at the University of Michigan have now produced the first ever molecular fingerprint of prostate cancer. They examined more than 700 prostate tissue samples from more than 50 men - covering normal tissue, tissue with benign change, and also tissues from both localised and aggressive prostate cancer. They found that more than 200 genes were expressed differently between normal and cancer tissue. Of these, some are already known to be involved in cancer, while others were completely new.

Of particular interest were two genes - hepsin and pim-1. The highest levels of hepsin were found in pre-cancerous tissue just before cancer develops, and the lowest in benign prostate tissue. Hepsin play a main role in tumour development. Pim-1, a known cancer-causing gene, was also highly expressed in prostate cancer tissue. Levels of hepsin and Pim-1 were significantly linked to prognosis, when the men's clinical histories were checked.

The researchers say that the discovery of prostate cancer's molecular fingerprint could lead to many new diagnostic tests. These could offer more to the patient than the current PSA (prostate specific antigen) test and can be used as a useful diagnostic tool.


'"/>




Page: 1

Related medicine news :

1. Better prostate cancer detection
2. Protective effects of tomatoes in prostate cancer
3. Early detection of prostate cancer
4. No link between blood groups and prostate cancer
5. Cure for osteoporosis in prostate cancer patients
6. Novel biopsy technique for prostate cancer
7. New diagnostic marker for prostate cancer
8. Inadequate proof to justify routine prostate screen
9. Combination regime may work against prostate cancer
10. Lifestyle linked to prostate cancer risk
11. Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International ... company, announced today that its iClinic V12.2 solution has achieved approval from National ... recently introduced PCMH 2017 standards which emphasize team-based care with a significant focus ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... the pharmaceutical and medical device sectors, today announced the winners of its 3rd ... Entrepreneurs) represent the most influential people in the healthcare industry today. , Out ...
(Date:5/23/2017)... ... May 23, 2017 , ... i2i Population Health, a national ... category winner, has named Daniel P. Bullington as chief technology officer. , “i2i ... and product offerings,” says Justin Neece, president. “Daniel is an excellent fit for ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... and Reconstructive Surgeon Dr. Kevin Sadati, is pleased to announce a new treatment ... collagen and elastin in their face, neck, and body through a virtually pain-free, ...
(Date:5/23/2017)... ... May 23, 2017 , ... MedTech ... in the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment at ... NextGen LifeLabs, a MedTech Group Purchasing vendor , will provide specialized equipment ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... May 4, 2017   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... the "Company"), today announced that the Company,s first quarter ... on Thursday, May 11, 2017, and that the Company ... 1:30 p.m. PT that afternoon. Management will provide an ...
(Date:5/3/2017)... 2017  Getinge, a leading global provider of ... and cost efficiency within healthcare and life sciences, ... practice demonstrating that intra-aortic balloon counterpulsation (IABC) appears ... patients. The single-center, retrospective, observational study showed that ... ® 50cc intra-aortic balloon (IAB) in contemporary ...
(Date:5/2/2017)... May 2, 2017  George Clinical, a leading full-service ... region, and Vector Oncology, a Memphis ... formally announced today that George Clinical has acquired ... has the dual purpose of strengthening the ability ... trial delivery solutions throughout the Asia-Pacific ...
Breaking Medicine Technology: